Folinic acid (leucovorin calcium) is the reduced, active form of folic acid (vitamin B9).
It is used as an antidote to methotrexate (MTX) toxicity and to reduce adverse effects of MTX therapy in cancer and autoimmune disease.
Unlike folic acid, it does not require activation by dihydrofolate reductase, meaning it can bypass the blockade caused by MTX.
โ๏ธ Mode of Action
MTX inhibits dihydrofolate reductase โ blocks conversion of folic acid to tetrahydrofolate โ impaired DNA synthesis.
Folinic acid โrescuesโ normal cells by replenishing tetrahydrofolate pools and allowing DNA and RNA synthesis to continue.
This โleucovorin rescueโ is the rationale for using folinic acid alongside or after high-dose MTX.
๐ Indications & Example Doses
Prevention of MTX side effects (e.g., in rheumatoid arthritis):
Folic or folinic acid reduces GI upset, oral ulcers, cytopenias. Commonly folic acid 5โ10 mg once weekly, but folinic acid can be used in intolerance.
High-dose MTX therapy (oncology):
Folinic acid 5 mg every 6 hours for 24 hours, started 12โ24 hours after MTX infusion. Then continued PO, IM, IV or IV infusion according to local protocol. Dose is adjusted depending on plasma MTX levels.
Suspected MTX overdosage:
Initial folinic acid dose equal to or greater than the MTX dose, given at a maximum IV rate of 160 mg/min. Continue with frequent dosing until plasma MTX level is safe. Always consult poisons information services and local oncology protocols.
๐ Interactions
See BNF for complete list.
May reduce efficacy of antifolate chemotherapy (e.g., trimetrexate, pyrimethamine).
โ ๏ธ Cautions
Use under specialist supervision in oncology/poisoning contexts.
Do not use simultaneously with intrathecal MTX (risk of enhanced CNS toxicity).
๐ซ Contraindications
See BNF โ none absolute, but inappropriate use can reduce MTX anticancer activity.